Drimva

Basecamp Research

Scientist I, Discovery

$110K–$140K

Boston · On-site · Full-time · Posted Oct 2, 2026

Education
PhD in molecular biology, biochemistry, genetics, bioengineering, or a life-sciences-related field, or an MSc with equivalent hands-on laboratory experience.

About the job

Develops and screens gene-editing tools and optimizes candidates for therapeutic development, collaborating with data science and AI teams.

What you'll do

  • Designs, builds, tests, validates, and engineers novel gene-editing proteins and tools.
  • Builds plasmid libraries and scalable cloning workflows; quantifies editing outcomes using molecular and sequencing assays.
  • Optimizes activity and specificity in human primary cells and cell lines, and helps establish lab documentation and SOPs.

What they ask for

  • PhD in molecular biology, biochemistry, genetics, bioengineering, or a life-sciences-related field, or an MSc with equivalent hands-on laboratory experience.
  • Experience with gene editing, NGS assay development, protein engineering, and cell therapy.
  • Experience with high-throughput cloning and DNA-construct production for cellular screening; mammalian cell culture, transfection, and cell-line generation.
  • Expertise in DNA/RNA extraction, PCR, ddPCR, NGS library preparation and QC; knowledge of gene-editing technologies and on/off-target analytics.

Nice to have

  • Experience contributing to a preclinical cell therapy program; flow cytometry expertise.
  • Experience integrating AI protein design tools with high-throughput wet-lab screening; NGS instrumentation, bioinformatics, or traceable data pipelines.

Pay

USD $110K - $140K base salary; USD $110K – $140K (Compensation; type not specified)

Tools

ddPCR, qPCR, flow-cytometry, NGS, PCR

AI focus

Collaborates with Data Science and AI teams; preferred experience integrating AI protein design tools with high-throughput wet-lab screening.

Model-written summary · the original posting is authoritative

First seen Oct 29, 2026 · Last verified Nov 6, 2026 (UTC)